Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Tuxil-D is a combination pharmaceutical product developed and manufactured by Fidson Healthcare, primarily indicated for the symptomatic relief of cough and cold symptoms. It is formulated as an oral syrup containing three active ingredients: dextromethorphan hydrobromide, a cough suppressant that acts on the cough center in the brain; phenylephrine hydrochloride, a decongestant that shrinks swollen nasal mucous membranes; and chlorpheniramine maleate, an antihistamine that reduces allergic symptoms like sneezing and runny nose. The product is widely marketed in West Africa as an over-the-counter (OTC) or prescription-branded generic for upper respiratory tract infections and allergic rhinitis.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Tuxil-D.